FDA approves Skyrizi for moderately to severely active Crohn’s disease

The FDA has approved AbbVie’s Skyrizi for the treatment of adults with moderately to severely active Crohn’s disease, according to a company press release.Previously approved in the United States for the treatment of adult patients with moderately to severely active plaque psoriasis and psoriatic arthritis, Skyrizi (risankizumab-rzaa, AbbVie) is the first interleukin-23 inhibitor to enter the Crohn’s disease market.“We are proud to offer the first new treatment option in 6 years for moderately to severely active CD, which may provide patients with a meaningful level ofRead More